Compare Crispr Therapeutics AG (CRSP) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ServiceNow Inc — how do they compare? Crispr Therapeutics AG trades at $51.4 (market cap $4.88B), while ServiceNow Inc trades at $140.7 (market cap $144.48B). The key difference: ServiceNow Inc is far larger — about 29.6× Crispr Therapeutics AG's market cap, and ServiceNow Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and ServiceNow Inc for 54 Days on average.
| CRSP | NOW | |
|---|---|---|
Market Cap | $4.88B | $144.48B |
Volume | 2,861,747 | 11,801,699 |
Sector | Health | Technology |
52-Week High | $74.92 | $189.26 |
52-Week Low | $44.34 | $83.00 |
Typical Hold Time | 77 Days | 54 Days |
Enterprise Value | $3.30B | $148.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
ServiceNow (NOW) trades at $139.75, up 1.29% with bullish technical momentum and strong institutional support. The company demonstrates robust revenue growth from $7.2B in 2022 to $13.3B in 2025, with consistent earnings beats and expanding AI capabilities driving investor optimism. Despite premium valuation metrics (P/E 86.17, P/S 9.75), the stock benefits from positive analyst sentiment with 87% buy ratings and a $146.04 consensus target.
NOW presents a compelling growth story with AI revenue surpassing $1B and projected to triple by 2029. However, elevated valuation multiples and competitive pressures from Atlassian and Palantir warrant caution. The stock's upside depends on sustained AI adoption and margin preservation amid increasing investment requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
